Integrating novel therapeutic monoclonal antibodies into the management of head and neck cancer

Authors

  • Julie E. Bauman MD, MPH,

    1. Department of Internal Medicine (Division of Hematology/Oncology), University of Pittsburgh Cancer Institute, Pittsburgh, Pennsylvania
    Search for more papers by this author
  • Robert L. Ferris MD, PhD

    Corresponding author
    1. Department of Otolaryngology, University of Pittsburgh Cancer Institute, Pittsburgh, Pennsylvania
    2. Department of Immunology, University of Pittsburgh Cancer Institute, Pittsburgh, Pennsylvania
    3. Cancer Immunology Program, University of Pittsburgh Cancer Institute, Pittsburgh, Pennsylvania
    • Corresponding author: Robert Ferris, MD, PhD, Cancer Immunology Program, University of Pittsburgh Cancer Institute, 5117 Centre Ave, Suite 2.26b, Pittsburgh, PA 15232; Fax: (412) 623-4840; ferrisrl@upmc.edu

    Search for more papers by this author

Abstract

Head and neck squamous cell carcinoma (HNSCC) is an immunosuppressive malignancy. Interest in developing novel immunotherapies in HNSCC has been reawakened by the success of cetuximab, a therapeutic monoclonal antibody (mAb) against the epidermal growth factor receptor, which likely relies on immune as well as antisignaling mechanisms. This review focuses on novel therapeutic mAbs in current clinical development against established mechanisms of immune evasion in HNSCC, targeting: 1) tumor antigens, with resultant potential to induce antibody-dependent cell-mediated cytotoxicity and T cell activation; 2) immunosuppressive cytokines; 3) costimulatory tumor necrosis factor–family receptors; and 4) coinhibitory immune checkpoint receptors. Clinical trials of immunotherapeutic mAbs as monotherapy, in combination with cytolytic standard therapies exposing tumor antigens or in combination with other immunomodulatory mAbs, are urgently needed in HNSCC. Cancer 2014;120:624–632. © 2013 American Cancer Society.

Ancillary